25 Sep 2017 07:00
25 September 2017
IXICO plc
("IXICO" or the "Company")
IXICO to provide specialist MR and PET imaging services in Phase II Huntington's disease clinical trial
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed a new contract with a North American based biopharmaceutical company. The contract value is £1.2m over a three year term.
IXICO will provide its technology enabled imaging services in a Phase II clinical trial of a novel therapeutic to treat people with Huntington's disease. As part of the study, IXICO will use its TrialTracker™ digital platform and scientific services to standardise the acquisition and collection of both MRI and PET scans acquired at specialist imaging centres across North America. This data will be analysed using IXICO's proprietary image analysis workflows and algorithms to evaluate patient eligibility, monitor patient safety and quantify drug effects.
Giulio Cerroni, Chief Executive of IXICO, said: "We are delighted to continue our successful track record in Huntington's disease clinical studies, providing compliant data standardisation, collection and analysis to support regulatory submissions. This first contract with a new customer also demonstrates the momentum we are building with our commercially led growth strategy focused on serving the needs of the biopharmaceutical industry".
For further information please contact:
IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer |
Tel: +44 20 3763 7499 |
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield / James Wolfe | Tel: +44 20 7408 4090 |
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan | Tel: +44 20 3727 1000 |
About IXICO
IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com
Ixico (IXI)